A 2-year randomized controlled trial with low-dose B-vitamin supplementation shows benefits on bone mineral density in adults with lower B12 status
When thyroid function tests change, the shifts are usually small and appear to relate to weight loss and broader metabolic changes
oral daily (Rybelsus) Tirzepatide Weekly injection (Mounjaro/Zepbound) Trial weight loss Tesofensine About 10% at 0.5 mg over 24 weeks (Phase 2 and Phase 3) Semaglutide About 15% over 68 weeks (STEP trials) Tirzepatide About 21% over 72 weeks (SURMOUNT trials) FDA status (June 2026) Tesofensine Not approved for any indication Semaglutide Approved (Wegovy for obesity, Ozempic for type 2 diabetes) Tirzepatide Approved (Zepbound for obesity, Mounjaro for type 2 diabetes) Main safety concern Tesofensine Heart rate rise, insomnia, mood Semaglutide Nausea, GI upset, rare pancreatitis Tirzepatide Nausea, GI upset, rare pancreatitis Direct head-to-head trials between tesofensine and GLP-1 drugs have not been run
Possible discussion points may include, We want to make sure that your treatment plan aligns with your goals, which includes managing your weight safely while undergoing chemotherapy
Sweeteners like maple syrup can be adjusted or used sparingly, especially if you prefer a less-sweet finish